ADEPT 2001.

Study characteristics
Methods	Single‐center, prospective DBRCT (double blind randomised control trial) conducted in Glasgow, UK Follow‐up: 8 wks Background ACEI? Yes
Participants	N=36 patients ≥18 years of age with CHF, caused by IHD or nonischemic dilated cardiomyopathy, receiving ACEI therapy for ≥4 wks Mean age: 63.5 y Females: 19.4% NYHA Class: II–IV LVEF: ≤35%
Interventions	Eprosartan 200 mg BID to target 400 mg BID (n=18) Placebo (n=18)
Outcomes	Primary: LVEF Secondary: haemodynamics; neurohormones
Notes	Funding source: Smithkline Beecham Pharmaceuticals
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not described.
Allocation concealment (selection bias)	Unclear risk	Not described.
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Not described.
Incomplete outcome data (attrition bias) All outcomes	Low risk	Reasons for withdrawal from study (6/36 patients) have been described.
Other bias	High risk	Funding source is manufacturer of eprosartan.